Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination - Wikidata - wikimedia - TriplyDB

Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

http://www.wikidata.org/entity/Q35206971

about

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease Growth factors in synaptic function.Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.Genetic Ablation of Soluble TNF Does Not Affect Lesion Size and Functional Recovery after Moderate Spinal Cord Injury in Mice.Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia Resilience and Vulnerability to Pain and Inflammation in the Hippocampus.Hippocampal TNFα Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy.IL7Rα contributes to experimental autoimmune encephalomyelitis through altered T cell responses and nonhematopoietic cell lineages Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain.Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis.Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis.Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination.The TNFα-Transgenic Rat: Hippocampal Synaptic Integrity, Cognition, Function, and Post-Ischemic Cell Loss.Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis Conditional ablation of myeloid TNF increases lesion volume after experimental stroke in mice, possibly via altered ERK1/2 signaling.Inhibition of astroglial NF-κB enhances oligodendrogenesis following spinal cord injury.Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice.Emerging immunopharmacological targets in multiple sclerosis.Opposing Functions of Microglial and Macrophagic TNFR2 in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions.Myeloid C/EBPβ deficiency reshapes microglial gene expression and is protective in experimental autoimmune encephalomyelitis.CNS Demyelination with TNF-α Blockers Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF.Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis.Correlation of inducible nitric oxide synthase (iNOS) inhibition with TNF-α, caspase-1, FasL and TLR-3 in pathogenesis of rabies in mouse model.Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia.Fingolimod induces neuroprotective factors in human astrocytes.Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.Human interferon regulatory factor 5 homologous epitopes of Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis induce a specific humoral and cellular immune response in multiple sclerosis patients.TNFR1 inhibition with a Nanobody protects against EAE development in mice.iRHOM2 takes control of rheumatoid arthritis.Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.

P2860

Q24293476-5FB6A4D0-B3AE-4E2E-90AC-9F11CEB6CCCA Q27334472-F5435364-B1F1-48F7-AFF4-7A61BAFD1AFB Q30449007-537A2C2B-CFF2-4849-A8DE-C52DE611ADB0 Q30610169-64717EBE-4D97-4B5C-B44A-41DF71DDE307 Q30833318-18CE7351-639F-4726-A147-1B7FD06F1865 Q33578973-61E3777C-BEDB-4166-B1E2-230265404F9E Q33624442-3B44516A-2105-4CBA-AB8D-BDE5BAD336FE Q33651396-3F8BD035-A49F-408E-AFDA-CCBBF93A3C6B Q33998401-47DB5D80-9867-4AC5-88CC-1352F6FB140C Q34203214-68B64CF4-077D-49D7-B0C0-D493D6EB5F2B Q34250544-9C48C4C7-0B18-4DC7-8506-BA234E24D109 Q34612387-3FD2B75D-46A1-4970-8106-78DD858B7A9D Q35012949-AD12CF43-52B7-4386-817F-DE2DD3BF0715 Q35108700-D10681ED-5C6E-45DD-A24F-A2DE9E3C7887 Q35549656-093CD26A-D883-4629-8AC9-505EA84056FC Q36606486-8A726524-EF52-4946-8AD0-651A968404EF Q36863995-0828CDC7-CFC8-445E-B4B4-22CF4AF67077 Q36868735-519FC801-C4A5-4DED-B9DC-E13513194FD5 Q36950333-67746F47-C268-4C76-8DF6-37BAA3C4E8FA Q37072728-71C1CB16-D1E8-45C8-BE16-66002A0B4067 Q37115937-92CBE030-A5DF-42C2-AAE6-E44F6214DDE9 Q37379859-4979630A-65D6-49EE-AC07-C03F009952E6 Q37424039-E136005B-5BE5-4B6F-B850-431DBE0AB4B6 Q37559970-CF535A36-8179-4251-900B-AEB615D2E33B Q37568350-D2270628-EAC6-46F7-A698-A23E99EA05FC Q37679511-990CE574-DC66-4E09-8CBD-68ACFC625C7F Q37708277-C977C1BC-5BBC-40B0-86FE-032A28168B5F Q37719132-14363C79-866C-4432-9FCC-16FAFAD33099 Q38401306-A584074D-D02C-49BB-9C7A-B5F8A7B85FC2 Q38765043-062C98BE-3118-415C-9B8A-825C28FA22FC Q38837294-D2AB6353-A7AF-476E-92CC-E9F4F8C3642E Q39352140-557F3087-8D6C-4D13-89F4-984615C1E28A Q40862930-868E5636-FC44-484B-809B-43289238088B Q41022804-317C3D87-787F-4388-9D23-7597745B36BB Q41576345-F4F43EFC-5096-4E40-87E5-5662A4363765 Q42001519-76BE3B66-028D-4BB5-9B10-57DD28499994 Q42181574-08CD9127-A80C-45F5-AA3B-10D4852B1664 Q42653357-1FA1F3BE-199D-4C85-AD96-69CFD50ABF97 Q43122596-64C6DFC9-A02C-45FE-AA12-8C9BA458559C Q44528190-82393C14-2C72-453E-B47A-95295FBCFA37

P2860

Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

http://www.wikidata.org/entity/Q35206971

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Inhibition of soluble tumour n ...... preservation and remyelination

@ast

Inhibition of soluble tumour n ...... preservation and remyelination

@en

type

label

Inhibition of soluble tumour n ...... preservation and remyelination

@ast

Inhibition of soluble tumour n ...... preservation and remyelination

@en

prefLabel

Inhibition of soluble tumour n ...... preservation and remyelination

@ast

Inhibition of soluble tumour n ...... preservation and remyelination

@en

P1433

Q35206971-0AF52279-51F9-4E33-80C1-C77753A0C603

P1476

Q35206971-6A676CA2-ED92-4CFB-8B60-0B08339CAF0B

P2093

Q35206971-0F9229B8-2501-4A77-B55A-96E4E05FA43D

Q35206971-350D3F09-38ED-4921-A8C3-AD687670D1F9

Q35206971-9304962A-C9C6-4617-97BE-FC52617BA8DE

Q35206971-BA1429B1-760A-4DA6-B965-443C96E8CB92

Q35206971-CDF604DF-6ED1-478E-8CA5-8B9B743F97B1

Q35206971-E0A774F5-C0D4-40F7-89D9-9F8831A320B3

Q35206971-EE694AE8-2210-4E02-B035-71A1460C1665

P2860

Q35206971-040D54D5-A676-49B9-BD46-585D8A71E730

Q35206971-050AEB73-9534-438C-98C8-616CABF773E3

Q35206971-0850847B-4AA6-4F17-BA92-194A2700BD76

Q35206971-0A35ABE9-E164-4C71-8A55-315347D3003A

Q35206971-0AA93A4D-F182-472F-AAD4-2E02C57227EC

Q35206971-0C8DBC7F-24C5-4028-ACB1-4B3EBA08778A

Q35206971-11468083-9F52-4FA6-977B-4F4666855685

Q35206971-14DCFABA-A0B3-4A4E-A6C7-74113508A526

Q35206971-1B49C609-310A-49CE-AC39-B26A6DF77114

Q35206971-27E9B656-DBC2-4472-9AE6-7DF51CE2557A

P304

Q35206971-7FC67371-9138-4C33-8FDE-D65D451F20E8

P31

Q35206971-182565CB-4CA9-424F-8E26-934696C6E540

P356

Q35206971-AAE39A6D-31F1-41D6-81D0-85A36D19E60B

P407

Q35206971-4BCD016A-8EFB-4080-B1C3-909B49C17538

P433

Q35206971-BE03A86E-15B6-40F4-B6BB-AC48F38E6540

P478

Q35206971-B92AF325-1B6E-4B3D-A119-F8D5FD3C9423

P577

Q35206971-1E59854D-E356-4A9F-A144-9DCAF3DCB288

P5875

Q35206971-B7B28F1A-EABA-4035-A6D1-0A2CB1D7377A

P698

Q35206971-0B8E01D0-020B-42A5-BBDF-76950F2CBC02

P921

Q35206971-8FD6A999-5FFE-47C4-927E-97E0FBCEBF99

Q35206971-b1f8ac87-675b-466f-8fd4-41f49daf3858

P932

Q35206971-1042EC20-A1A3-4871-B8AF-BBEC2BA32107

P356

P1433

P1476

Inhibition of soluble tumour n ...... preservation and remyelination

@en

P2093

Anna Dellarole

http://www.w3.org/2001/XMLSchema#string

David E Szymkowski

http://www.w3.org/2001/XMLSchema#string

Jessica Jopek Ashbaugh

http://www.w3.org/2001/XMLSchema#string

John R Bethea

http://www.w3.org/2001/XMLSchema#string

Roberta Brambilla

http://www.w3.org/2001/XMLSchema#string

Roberta Magliozzi

http://www.w3.org/2001/XMLSchema#string

Shaffiat Karmally

http://www.w3.org/2001/XMLSchema#string

P2860

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants

Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pat

Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune re

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

Axonal transection in the lesions of multiple sclerosis

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha

Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology.

Tumor necrosis factor signaling.

P304

2736-2754

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWR199

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 9

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51640289

http://www.w3.org/2001/XMLSchema#string

P698

21908877

http://www.w3.org/2001/XMLSchema#string

P921

experimental autoimmune encephalomyelitis

P932

3170538

http://www.w3.org/2001/XMLSchema#string